Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Yasuo Urata"'
Autor:
Kanae Abe, Yasuo Urata, Natsuki Yanase, Hiroyuki Mizuguchi, Akikazu Asada, Hideki Hayakawa, Fuminori Sakurai
Publikováno v:
Biologicalpharmaceutical bulletin. 41(10)
In recent times, oncolytic viruses expressing an extraneous gene have attracted great interest; in fact, they have been engaged in multiple applications, such as medicine for cancer. Our group made an oncolytic adenovirus, namely, OBP-301, for use in
Autor:
Yuuri Hashimoto, Toshiyoshi Fujiwara, Masahiko Nishizaki, Hiroyuki Kishimoto, Hiroshi Tazawa, Shinji Kuroda, Takeshi Nagasaka, Shuya Yano, Yasuo Urata, Futoshi Uno, Yasuhiro Shirakawa, Robert M. Hoffman, Shunsuke Kagawa
Publikováno v:
Clinical Cancer Research. 19(23):6495-6505
Purpose: Because chemoradiotherapy selectively targets proliferating cancer cells, quiescent cancer stem–like cells are resistant. Mobilization of the cell cycle in quiescent leukemia stem cells sensitizes them to cell death signals. However, it is
Autor:
Yasuo Urata, Ryozo Kuwano, Akira Ogose, Toshiyoshi Fujiwara, Gui Dong Li, Takashi Ariizumi, Tetsuo Hotta, Hiroyuki Kawashima, Naoto Endo
Publikováno v:
Cancer Sci
This study investigated the pathway underlying the antitumor activity of telomelysin, a telomerase‐dependent, replication‐selective oncolytic adenovirus, in soft tissue sarcoma cells. Treatment with telomelysin alone resulted in simultaneous indu
Autor:
Yuuri Hashimoto, Shinji Kuroda, Shunsuke Kagawa, Ryosuke Yoshida, Yasuo Urata, Toru Kojima, Futoshi Uno, Yasumoto Yamasaki, Hiroyuki Mizuguchi, Shuya Yano, Akira Ohtsuru, Toshiyoshi Fujiwara, Hiroshi Tazawa
Publikováno v:
European Journal of Cancer. 48:2282-2291
Oncolytic viruses engineered to replicate in tumour cells but not in normal cells could be used as tumour-specific vectors carrying the therapeutic genes. We previously developed a telomerase-specific oncolytic adenovirus, OBP-301, that causes cell d
Autor:
Toshifumi Ozaki, Yuuri Hashimoto, Tsuyoshi Sasaki, Shuya Yano, Akira Yoshida, Shunsuke Kagawa, Ryosuke Yoshida, Toshiyoshi Fujiwara, Jo Hasei, Yasuo Urata, Yuki Morimoto, Hiroshi Tazawa, Toshiyuki Kunisada, Futoshi Uno
Publikováno v:
Okayama Igakkai Zasshi (Journal of Okayama Medical Association). 124:105-110
Purpose: Tumor-specific replication-selective oncolytic virotherapy is a promising antitumor therapy for induction of cell death in tumor cells but not of normal cells. We previously developed an oncolytic adenovirus, OBP-301, that kills human epithe
Autor:
Tetsuo Hotta, Akira Ogose, Naoto Endo, Takashi Ariizumi, Toshiyoshi Fujiwara, Guidong Li, Hiroyuki Kawashima, Yasuo Urata, Yongjun Xu
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 137:1037-1051
A telomerase-specific oncolytic adenovirus, Telomelysin, can selectively kill cancer cells, and be attenuated in normal cells. We herein describe the oncolytic effect of Telomelysin on human osteosarcoma both in vitro and in vivo. The anti-tumor effe
Autor:
Toshiyoshi Fujiwara, Takanori Oyama, Hiroshi Tazawa, Shunsuke Kagawa, Terutaka Tanimoto, Morimichi Tani, Hiroshi Noso, Takuo Noda, Yasuo Urata
Publikováno v:
Cancer Research. 78:3177-3177
Background: Neuroblastoma (NB) is a primary malignant tumor of the peripheral sympathetic nervous system. High-risk NB patients show an unfavorable clinical outcome, even after treatment with intensive chemotherapy and aggressive surgical resection.
Autor:
Toshiyoshi Fujiwara, Yasuo Urata, Yuichi Watanabe, Hitoshi Kawamura, Noriaki Tanaka, Shunsuke Kagawa, Katsuyuki Nagai, Yuuri Hashimoto
Publikováno v:
Cancer gene therapy. 19(11)
Replication-selective oncolytic viruses are being developed for human cancer therapy. We previously developed an attenuated adenovirus (OBP-301, Telomelysin), in which the human telomerase reverse transcriptase promoter element drives expression of E
Autor:
Kazuhisa Sugiu, Joe Hasei, Toshifumi Ozaki, Shuhei Osaki, Toshinori Omori, Kouji Uotani, Toshiyoshi Fujiwara, Tomohiro Fujiwara, Hiroshi Tazawa, Yasuo Urata, Tadashi Komatsubara, Yasuaki Yamakawa, Toshiyuki Kunisada
Publikováno v:
Cancer Research. 76:4677-4677
Background: Osteosarcoma is a primary malignant bone tumor. Despite recent advances in multi-agent chemotherapy and aggressive surgical resection, the poor response to chemotherapy often contributes to poor prognosis in osteosarcoma patients. Therefo
Autor:
Yuuri Hashimoto, Toshiyoshi Fujiwara, Tsuyoshi Sasaki, Hiroshi Tazawa, Toshiyuki Kunisada, Yasuo Urata, Joe Hasei, Toshifumi Ozaki
Publikováno v:
Cancer Research. 73:3316-3316
Bone and soft tissue sarcomasare the third most common cancer in children and account for 15.4% of all childhood malignancies. About one fourth of the patients show a poor response to conventional chemo-radiotherapy, resulting in subsequent recurrenc